Mental health on Valentine's Day
Katie Yesis is the manager of community-based behavioral health at Trillium Place. She stopped by WMBD This Morning to talk with our Shabnam Danesh about how to practice self-care and avoid stress over the holiday.
For more information, you can visit trilliumplacehealth.org, carle.org, or call the access center hotline at 1-888-311-0321.
Love WMBD This Morning? We love you, too. And you can have all the hijinks delivered to your inbox every weekday morning. Sign up and subscribe to our Daily Newsletter.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Washington Post
a day ago
- Washington Post
A critical health care fight in Congress is just beginning
Good morning, Early Birds. Like Coldplay, we hope this newsletter will be everywhere soon. Send tips to earlytips@ Thanks for waking up with us. In today's edition … A health care fight is brewing on Capitol Hill … Democrats' bleak options to fight redistricting in Texas … A French legal drama we did not expect … but first …
Washington Post
17-07-2025
- Washington Post
Japanese walking, protein tips and wildfire smoke: The week in Well+Being
You're reading our weekly Well+Being newsletter. Sign up here to get it delivered to your inbox every Thursday. Have you taken a walk today? Here at Well + Being, we're excited about a 'new' walking technique that's actually been around for decades. And it's worth rediscovering. As you know, exercise is so important for health and longevity, but it's not always convenient or easy to schedule. That's why we love to hear about workouts that maximize the benefits — better mood, sleep, muscle strength and blood pressure, anyone?— and doesn't take that long. This one, called 'Japanese walking' can be done in just 30 minutes a day. And as an added bonus, summer can be the perfect time to take a walk in nature (which has its own mental health benefits) while also hitting your exercise goals. We've even scheduled a Live Chat on Tuesday at noon Eastern to answer your questions about how to use walking to get in shape. Please join us! But before that …
Yahoo
17-07-2025
- Yahoo
OSE Immunotherapeutics lance une Newsletter pour les investisseurs individuels
OSE Immunotherapeutics Launches Newsletter for Individual Shareholders NANTES, France, July 17, 2025, 6:30pm CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I) that address the unmet patient needs, today launched the inaugural edition of its Newsletter, designed specifically for individual shareholders and investors in France and internationally. " This year, OSE Immunotherapeutics celebrates the 10th anniversary of its listing on Euronext Paris and we are delighted to introduce this new communication channel for our valued individual shareholders" said Fiona Olivier, Chief Corporate Affairs & Investor Relations Officer of OSE Immunotherapeutics. " Beyond providing updates on Company developments, the Newsletter gives us an opportunity to shine a spotlight on our teams and offer deeper insights into topics that are typically only touched on in press releases. It's also a way for us to express our appreciation for the continued trust and support of our investor community. " Published regularly in French and English, the Newsletter will be available in the 'Investors' section of the OSE Immunotherapeutics website. To subscribe to receive our Newsletters: ABOUT OSE IMMUNOTHERAPEUTICSOSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I) that address the unmet patient needs of today and tomorrow. We partner with leading academic institutions and biopharmaceutical companies in our efforts to develop and bring to the market transformative medicines for people with serious diseases. OSE Immunotherapeutics is based between Nantes and Paris and is quoted on Euronext. Additional information about OSE Immunotherapeutics assets is available on the Company's website: Click and follow us on LinkedIn. Follow us on Fiona Dé France Contact Media: FP2COMFlorence Portejoiefportejoie@ 6 07 768 283 U.S. Contact Media:RooneyPartners LLCKate Barrettekbarrette@ 212 223 0561 Forward-looking statements This press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics' management considering its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate. These forward-looking statements include statements typically using conditional and containing verbs such as 'expect', 'anticipate', 'believe', 'target', 'plan', or 'estimate', their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics' shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on April 30, 2025, including the annual financial report for the fiscal year 2024, available on the OSE Immunotherapeutics' website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements. Attachment EN_250717_Newsletter_vfSign in to access your portfolio
